Print

The IGBA Biosimilars Committee has developed a communication slide deck on biosimilar medicines

2017-11-09 - If you wish to use any part of this slide deck, please contact us at  This email address is being protected from spambots. You need JavaScript enabled to view it. . We would be happy to share this with you.

Print

Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee

June 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of a regulatory framework for biosimilar medicines in Europe through her 15 years of experience with the Biosimilar Medicines Group, a Medicines for Europe sector group. Ingrid has a wealth of international regulatory knowledge and business and scientific experience.

Print

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

March 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency of switching in clinical practice is scarce, no evidence from clinical trials or post marketing surveillance data has found that switching to or from different biotherapeutics leads to safety concerns.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.